Last reviewed · How we verify
Human regular insulin intravenously
At a glance
| Generic name | Human regular insulin intravenously |
|---|---|
| Also known as | Insulin Actrapid, NovoNordisk, Denmark |
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes (NA)
- Neural Mechanism of Aldosterone-induced Insulin Resistance (PHASE4)
- Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients (PHASE2, PHASE3)
- KP-10 and Insulin Secretion in Men (PHASE3)
- Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome (PHASE1)
- Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity (NA)
- Exenatide for Stress Hyperglycemia (PHASE2, PHASE3)
- Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human regular insulin intravenously CI brief — competitive landscape report
- Human regular insulin intravenously updates RSS · CI watch RSS
- Medical University of Graz portfolio CI